REGN Financial Facts
Weighted average shares outstanding, basic and diluted: 91.05MNet loss before income tax benefit: -61.8M
See Full Income Statement
Common Stock: 90K
Other assets: 13.02M
See Full Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) Earnings
|
Expand Research on REGN
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +39.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -1.8% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/4/22 | Q222 | N/A | $10.06 | N/A | N/A | $2.8B | N/A | N/A | N/A | ||
| 5/4/22 |  |
Q122 | $11.49 | $10.04 | +$1.45 | $2.97B | $2.73B | N/A |  | | Details |
| 2/4/22 | |
Q421 | $23.72 | $18.37 | +$5.35 | $4.95B | $4.42B | N/A | | | Details |
| 11/4/21 | |
Q321 | $15.37 | $9.22 | +$6.15 | $3.45B | $2.76B | N/A | | | Details |
| 8/5/21 | |
Q221 | $25.80 | $17.69 | +$8.11 | $5.14B | $3.89B | N/A | | | Details |
| 5/6/21 | |
Q121 | $9.89 | $9.00 | +$0.89 | $2.53B | $2.55B | N/A | | | Details |
| 2/5/21 | |
Q420 | $9.53 | $8.43 | +$1.10 | $2.42B | $2.42B | N/A | | | Details |
| 11/5/20 | |
Q320 | $8.36 | $7.13 | +$1.23 | $2.29B | $2.09B | N/A | | | Details |
